Author:
Akce Mehmet,Liu Yuan,Zakka Katerina,Martini Dylan J.,Draper Amber,Alese Olatunji B.,Shaib Walid L.,Wu Christina,Wedd Joel P.,Sellers Marty T.,Bilen Mehmet A.,El-Rayes Bassel F.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference64 articles.
1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020
2. Molecular targeted therapies in hepatocellular carcinoma;Llovet;Hepatology,2008
3. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008
4. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017
5. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial;El-Khoueiry;Lancet,2017
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献